Healthy Returns: AbbVie is the newest potential weight loss drug market player

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.The booming weight loss drug market has gained a new potential competitor. AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the pharmaceutical giant will pay Gubra $350 million upfront ...